Lewy body dementia is a disease linked to abnormal protein deposits called Lewy bodies in the brain.
Lewy bodies affect chemicals in the brain whose changes, in turn, can lead to problems with thinking, movement, behavior, and mood.
Lewy body dementia is the second most common type of progressive dementia after Alzheimer’s disease dementia.
There are no approved treatments for Lewy body dementia, and it is important to find therapies for this and related brain disorders.
In a recent study at the University of North Carolina at Chapel Hill, researchers found that people with mild-to-moderate Lewy body dementia (LBD) had a big improvement in cognition when they took the drug neflamapimod three times daily.
The trial of neflamapimod in dementia with Lewy bodies is very encouraging. One researcher of the study is Jeffrey L. Cummings, MD, ScD.
As a Lewy Body Dementia Association (LBDA) Center of Excellence, UNC Neurology served as one of the phase 2 study sites.
The team is expected to be included as a study site for the planned phase 3 clinical trial.
They say the exciting results of the phase 2 study demonstrated the benefit of the new drug neflamapimod for cognition in dementia with Lewy bodies.
This will bring hope to patients and caregivers.
If these findings are confirmed in a phase 3 study, the potential impact for patients with dementia with Lewy bodies will be significant.
Copyright © 2021 Knowridge Science Report. All rights reserved.
